Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Arqule Inc (ARQL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 131,536
  • Shares Outstanding, K 87,110
  • Annual Sales, $ 4,710 K
  • Annual Income, $ -22,720 K
  • 36-Month Beta 1.38
  • Price/Sales 28.12
  • Price/Cash Flow N/A
  • Price/Book 17.88

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.22 +22.95%
on 11/13/17
1.57 -4.46%
on 12/04/17
+0.29 (+23.97%)
since 11/10/17
3-Month
0.97 +54.64%
on 10/31/17
1.57 -4.46%
on 12/04/17
+0.33 (+28.21%)
since 09/11/17
52-Week
0.92 +63.04%
on 05/01/17
1.68 -10.71%
on 01/25/17
+0.17 (+12.78%)
since 12/09/16

Most Recent Stories

More News
ArQule Announces Dosing in a Registrational Trial of FGFR Inhibitor, Derazantinib, for Treatment of Intrahepatic Cholangiocarcinoma

ArQule, Inc. (Nasdaq: ARQL) today announced dosing of the initial patients in a registrational trial with its FGFR inhibitor, derazantinib (ARQ 087) in FGFR2 fusion driven second-line intrahepatic...

ARQL : 1.50 (-0.66%)
Cancer Immunotherapy Technology Projected to Create Further Growth

According to data provided by Allied Market Research, the global cancer immunotherapy market is expected to grow to $117.14 billion by 2022, growing at a CAGR of 14.5 percent from the time period of 2016...

CLDX : 3.08 (+1.65%)
ARQL : 1.50 (-0.66%)
RGBP : 0.0659 (-11.54%)
RGBPP : 0.0560 (unch)
ECYT : 4.97 (+0.61%)
CASI : 3.52 (+1.73%)
ArQule, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 9, 2017 / ArQule, Inc. (NASDAQ: ARQL) will be discussing their earnings results in their Q3 Earnings Call to be held on November 9, 2017 at 9:00 AM Eastern Time.

ARQL : 1.50 (-0.66%)
ArQule Reports Third Quarter 2017 Financial Results

ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the third quarter of 2017.

ARQL : 1.50 (-0.66%)
ArQule Announces $9.5 Million Private Placement of Preferred Stock

--Ran Nussbaum, Managing Partner and co-founder of The Pontifax Group, joins ArQule Board

ARQL : 1.50 (-0.66%)
FDA Grants Rare Pediatric Disease Designation to ArQule's Miransertib (ARQ 092) for the Treatment of Proteus Syndrome

ArQule, Inc. (Nasdaq: ARQL) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to miransertib (ARQ 092) for the treatment of Proteus...

ARQL : 1.50 (-0.66%)
ArQule To Report Third Quarter 2017 Financial Results On November 9, 2017

ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the third quarter 2017 before the market opens on Thursday, November 9, 2017. The Company will hold...

ARQL : 1.50 (-0.66%)
ArQule Announces $15.7 Million Private Placement of Common Stock

ArQule, Inc. (NASDAQ: ARQL) today announced the closing of a private placement with certain institutional investors, with leading participation by BVF Partners L.P., pursuant to which the...

ARQL : 1.50 (-0.66%)
ArQule to Present at the Cantor Fitzgerald Global Healthcare Conference on September 26, 2017

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, M.D., Head of Research and Development and Chief Medical Officer, will present...

ARQL : 1.50 (-0.66%)
ArQule Reports Second Quarter 2017 Financial Results

ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the second quarter of 2017.

ARQL : 1.50 (-0.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead clinical-stage...

See More

Key Turning Points

2nd Resistance Point 1.57
1st Resistance Point 1.54
Last Price 1.50
1st Support Level 1.47
2nd Support Level 1.43

See More

52-Week High 1.68
Last Price 1.50
Fibonacci 61.8% 1.39
Fibonacci 50% 1.30
Fibonacci 38.2% 1.21
52-Week Low 0.92

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.